Edison Pharmaceuticals has launched a phase 2b trial to test its small-molecule drug EPI-743 in adults with Friedreich's ataxia
|Update (Dec. 30, 2013): This study of EPI-743 in Friedreich's ataxia is ongoing but is no longer open to new participants.|
Edison Pharmaceuticals has launched a phase 2b clinical trial of its experimental drug EPI-743 in adults with Friedreich's ataxia (FA) to assess whether the drug has positive effects on visual function, neurological and neuromuscular function, and disease-associated biomarkers.
EPI-743 is a small-molecule, oral drug that is designed to enter the central nervous system and synchronize (improve) energy generation in mitochondria, the energy-producing subunits in cells. It is being developed by Edison, which is located in Mountain View, Calif., and Utrecht, Netherlands.
Investigators plan to enroll 60 adults, ages 18-45 years. Trial participants will be assigned to take either 200 or 400 milligrams of EPI-743, or a placebo, three times a day for six months. In a planned extension study, all trial participants will take EPI-743.
Prospective participants must have a genetically confirmed diagnosis of FA and meet additional trial inclusion criteria.
The trial is being conducted at three centers in the United States. (At the time this article was posted, not all study sites had started recruiting for the trial.)
Children's Hospital of Philadelphia
Contact: Lauren Sayer at email@example.com
University of California, Los Angeles
Los Angeles, Calif.
Contact: Maria Casado at firstname.lastname@example.org
University of South Florida
Contact: Kelly Sullivan at email@example.com
For details about the new trial, see:
Or, go to ClinicalTrials.gov, and enter NCT01728064 in the search box.
About Clinical Trials
A clinical trial is a test, in humans, of an experimental treatment. Although it's possible that benefit may be derived from participating in a clinical trial, it's also possible that no benefit, or even harm, may occur.